ChromaDex, a natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, animal health, cosmetic and pharmaceutical industries, has announced the initiation of the first human clinical study in the U.S. for PURENERGY.PURENERGY is a patented co-crystal ingredient comprised of caffeine and ChromaDex's pTeroPure® pterostilbene that forms a unique crystalline structure that is said to have superior benefits compared to the two individual components alone. Recently, caffeinated energy products have been coming under increased regulatory and political scrutiny regarding the possible risks of consuming high amounts of caffeine, the company said: this patented new ingredient technology should allow formulators of caffeinated energy products the opportunity to reduce the total amount of caffeine without affecting the consumers' product experience.
The human study is intended to confirm an earlier animal study which showed PURENERGY had a 6-8 times longer half-life compared to caffeine alone. The results of the animal study are said to suggest that PURENERGY may provide longer sustained energy and alertness with reduced amounts of caffeine and without the "crash" typically experienced when ingesting caffeinated energy products.
The clinical trial is designed to determine the safety, relative bioavailability and pharmacokinetics of PURENERGYs compared to pterostilbene and caffeine alone. The start of this trial in the U.S. follows the recent commercial launch of PURENERGY.
Given the co-crystal formulation with pTeroPure, PURENERGY is also claimed to have additional functional health benefits that include cognitive function, antioxidant activity, heart health and weight management support. ChromaDex's patented pTeroPure is described as a 99 percent pure nature-identical pterostilbene with seven patents pending or issued.
